Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan's Manufacturing Maelstrom: Trans-Atlantic Recalls And Personal Citation By Gottlieb

Executive Summary

GMP quality, once Mylan's calling card, is now an ongoing problem, forcing product discontinuations and apologies to customers. Firm's valsartan products have European certificate of suitability suspended as Morgantown, W.Va. facility draws US FDA warning letter.

You may also be interested in...



FDA Warning Letters Hit Small OTC, Large Pharma Firms With Same Citations In FY 2019

Inadequate process controls and faulty failure investigations were the top GMP violations found in warning letters sent in FY 2019 to companies large and small.

Visible Particles, Drug Shortages, DSCSA Spotlighted In CDER’s 2020 Quality/GMP Guidance Agenda

The US FDA plans to issue new guidance this year on visible particle inspections, drug shortage risk management plans, and several guidances related to DSCSA implementation, one on identifying trading partners and the other on establishing verifications systems.

Swift And Nimble – Alembic Laps Up US Valsartan Windfall In Q2

Alembic moved fast and seized supply opportunities for valsartan, the hypertension drug that has seen shortages in the US, though management maintains that fundamental changes to the US market are there to stay given the backdrop of buying power of distributors.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS124304

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel